Anti-c antibodies are immune proteins your body produces against a specific marker on red blood cells called the “little c” antigen, part of the Rh blood group system. In pregnancy, these antibodies can cross the placenta and attack your baby’s red blood cells if the baby carries the c antigen, potentially causing a condition called hemolytic disease of the fetus and newborn (HDFN). While severe cases are rare, anti-c is managed similarly to the more well-known anti-D antibody because it can, in some pregnancies, cause serious fetal anemia.
The Rh System Beyond “Positive” and “Negative”
Most people know about the D antigen, the one that determines whether you’re Rh-positive or Rh-negative. But the Rh blood group system is far more complex than that single marker. It includes several other antigens: D, c, E, C, and e, ranked in that order by how likely they are to trigger an immune response. The “little c” antigen is one of these, and it’s common in the general population.
When your red blood cells lack the c antigen but you’re exposed to blood that carries it, your immune system can recognize it as foreign and produce anti-c antibodies. This process is called alloimmunization, and once it happens, it cannot be reversed. Your immune system remembers the antigen permanently.
How You Develop Anti-c Antibodies
There are two main ways this sensitization happens. The first is through a blood transfusion. If you received red blood cells at some point that carried the c antigen and your own cells don’t, your body may have quietly built antibodies against it. The antibody levels can be so low they’re undetectable for years, only to surge when you encounter the antigen again.
The second, and more relevant to pregnancy, is fetomaternal hemorrhage. During pregnancy, small amounts of your baby’s blood routinely cross the placenta into your bloodstream. A volume as small as 0.1 mL of incompatible blood is enough to trigger alloimmunization. This crossover is especially likely during miscarriage, pregnancy termination, abdominal trauma, ectopic pregnancy, or procedures like external cephalic version (when a doctor manually turns a breech baby).
The critical detail: the first pregnancy with an incompatible baby usually isn’t the dangerous one. During that pregnancy, your immune system is encountering the antigen for the first time and producing a relatively slow, mild response. It’s in a subsequent pregnancy, when a second baby also carries the c antigen, that your immune system mounts a rapid, aggressive response. Antibody production ramps up quickly, and those antibodies cross the placenta in greater quantities.
What Anti-c Antibodies Do to the Baby
Once anti-c antibodies cross the placenta, they attach to the baby’s red blood cells and mark them for destruction by the baby’s own immune system. This breakdown of red blood cells is called hemolysis. As the baby loses red blood cells faster than it can replace them, anemia develops.
Mild cases may cause jaundice after birth, which is treatable with phototherapy. More serious anemia, though, forces the baby’s body to produce red blood cells from organs that don’t normally do that job, like the liver and spleen, causing them to enlarge. In the most severe scenario, the baby can develop hydrops fetalis, a dangerous condition involving fluid buildup in the baby’s tissues and body cavities. There are case reports of hydrops and fetal death from anti-c, though severe HDFN from this antibody is considered very rare.
Anti-D remains the most common cause of severe hemolytic disease. But because anti-c has demonstrated the ability to cause clinically significant harm, medical guidelines call for managing it with the same level of vigilance.
How Your Pregnancy Will Be Monitored
Anti-c antibodies are typically discovered during routine prenatal blood screening, which checks for irregular antibodies in your blood. Once detected, your care team will track the antibody titer, a measure of how concentrated the antibodies are. For anti-D, the critical threshold that triggers closer fetal monitoring is generally between 1:8 and 1:32. Anti-c is typically managed with similar thresholds, though your provider may use slightly different cutoffs based on your specific history. If your titer stays at or below 1:8, you’ll likely have repeat blood draws every four weeks to watch for changes.
When titers rise above the critical level, or in any subsequent affected pregnancy, monitoring shifts to tracking the baby directly. The standard tool is a specialized Doppler ultrasound that measures blood flow speed in the baby’s middle cerebral artery (MCA). When a baby becomes anemic, its blood gets thinner and flows faster. An MCA peak systolic velocity above 1.5 times the expected median for the baby’s gestational age signals moderate to severe anemia. This test is remarkably accurate. In a landmark study published in the New England Journal of Medicine, it detected moderate or severe anemia with 100% sensitivity, with a false positive rate of only 12%.
This Doppler measurement has largely replaced the older method of testing amniotic fluid, meaning your baby’s anemia can be tracked without an invasive procedure in most cases.
Determining If Your Baby Is at Risk
Not every baby will carry the c antigen. If the baby’s father doesn’t carry it, the baby won’t either, and the antibodies pose no threat. Paternal blood typing can help clarify this. If the father does carry the c antigen, or if paternity is uncertain, the focus turns to figuring out the baby’s blood type directly.
Non-invasive prenatal testing using cell-free fetal DNA from a maternal blood sample can determine the baby’s c antigen status. Early research showed a combined accuracy of about 96% for determining the baby’s Rh C/c type this way, with some methods using cell-free DNA from maternal plasma achieving 100% accuracy. Availability of this specific test varies by region and institution, so it may not be offered everywhere as a standard option.
Treatment When Anemia Is Detected
If Doppler monitoring shows the baby is becoming significantly anemic, the primary treatment before birth is intrauterine transfusion (IUT). During this procedure, specially prepared red blood cells are transfused directly to the baby through the umbilical cord, guided by ultrasound. It is an invasive procedure, but it can reverse fetal anemia and even resolve hydrops fetalis in some cases.
IUTs are generally started after 22 to 24 weeks of gestation and may need to be repeated every two to four weeks until the baby is mature enough for delivery. The transfused blood is carefully matched to avoid the specific antigens your antibodies target. In the case of anti-c, this means using c-negative red blood cells so the transfused blood won’t be destroyed by your antibodies. The blood is also specially processed to be safe for the baby: freshly collected, filtered to remove white blood cells, and irradiated.
After birth, affected babies may still need treatment for anemia or jaundice. Phototherapy (light treatment) handles most jaundice, and some newborns require exchange transfusions to quickly remove the antibody-coated red blood cells and replace them with compatible ones. The severity at birth depends on how aggressive the antibody response was during pregnancy and how early the baby is delivered.
Anti-c vs. Anti-C: The Naming Matters
The Rh system uses both uppercase and lowercase letters to distinguish different antigens, which can be confusing. Anti-c (“little c”) and anti-C (“big C”) target two different antigens entirely. Of the Rh antigens, D is the most immunogenic, meaning it’s the most likely to provoke an immune response. The c antigen ranks second. Big C is lower on the list. Both can cause HDFN, but anti-c has a stronger track record of causing clinically significant disease, which is why it receives more attention in prenatal care.